{"name":"Syndeio Biosciences, Inc","slug":"syndeio-biosciences-inc","ticker":"","exchange":"","domain":"syndeio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AGN-241751","genericName":"AGN-241751","slug":"agn-241751","indication":"Atrial fibrillation for stroke prevention","status":"phase_2"}]}],"pipeline":[{"name":"AGN-241751","genericName":"AGN-241751","slug":"agn-241751","phase":"phase_2","mechanism":"AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNWkY4dmlMM3l1WGxhbHVzdEh4bUprYjhEaTQ5WWhuRzdRbkoxRXNEZEZkTkNtM0YxRnNFY1FpcDhCWm9ZYndYVGU4Zy1pSnh4MjlpT21qNHBRR0lCZ0JwY0V1Xzh5bHJOTnhRRDZBa2hydzdYVVRKMzEyTnlJcGxINjRVVG5tUXhrRHVwR0xTZWdYNDVrOTZLeTBOUnF0VmVz?oc=5","date":"2025-11-10","type":"pipeline","source":"cen.acs.org","summary":"Syndeio targets the brain’s connections - cen.acs.org","headline":"Syndeio targets the brain’s connections","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPeUViVGVZZHF4cXNnV3JMcGlRc0J1YkVTRDJIWkxJVXh0Zl9TT0hFMUlwVXYtNkd1RzhaakszVjZ5bktrOFczaGU0SUh3N09obHlmbVRuUU82eWZWY3dNMjJpOW5WdDlyTDhhU1ZWcWk1NTc2WVYyZFRlWHdXb3ZscVhHbUNCYzVyUDFMZ2hFd0Q4R3E2MndIZ3R5LU8ydHhfVTJObW9Rbmh4cmFncVhLTV9PUE42RjRnUjNIRlRIV2pIRkJ0em9v?oc=5","date":"2025-11-04","type":"pipeline","source":"businesswire.com","summary":"Syndeio Biosciences Appoints Aaron Koenig, M.D., as Chief Medical Officer - businesswire.com","headline":"Syndeio Biosciences Appoints Aaron Koenig, M.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNaGxsaEtQQmFlTU4yNTNMaU9OX3o1bEhfNThnRmpJZGdwYUVIaHFZLXkyc0xXbTNqc0dkWFpTYnEyVUVfOG5PU1AwY0lLclYwVVNPU2FxTWQtQUI2WXI3VzIzVmNsOXg0SUpnWHpaXzRCaFJtenhGWjZlaHNNMndYM0QtYkwwR25URlUyc2RkRjNuQ19ZLTRPeS01NUtiYWFfdXp2dnpJbDIyQQ?oc=5","date":"2025-06-04","type":"pipeline","source":"BioXconomy","summary":"Syndeio Biosciences emerges with $90m+ funding to combat CNS disorders - BioXconomy","headline":"Syndeio Biosciences emerges with $90m+ funding to combat CNS disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5oN2xRaWZqVjEzVWV2ZklZNm5xYVZidVRWWkZadGxFdDU1MDlOVHNrUkkzN2l3Mk9HNkZfWHJxZGpYLTRGR2JlNjFQTVdiR1RiRHRHTTJIMVk2Qkh4anJ6bg?oc=5","date":"2025-06-03","type":"pipeline","source":"The Pharma Letter","summary":"Syndeio Biosciences - The Pharma Letter","headline":"Syndeio Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOT2dkY29KV0dycnBER09ZNGU1Rll5OFYzcG9PMkNSV0N3Rkc1eXUzNzVRVVhJb0VFWkU5VmFfMFFPYkw3WHoxT2FlY19XYkxRQzVySkhfeHZCbHdUckpKZjBVSWR3MTNSaFVoWDEtNDhvVFBqVGFJQWxveWc2VzN1anpLckJzWjR5YnpKbjFON3VlbXBXc1lzcTdWaHpMYXBGeXc?oc=5","date":"2025-05-29","type":"pipeline","source":"cen.acs.org","summary":"Syndeio Biosciences launches with molecules to target the synapse - cen.acs.org","headline":"Syndeio Biosciences launches with molecules to target the synapse","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPRy1GVWxpUGx1cUFZS3NVbm1DNWxYODZWbjlFY2RubnFTc1RucXAzbDNNOXBZcnVaVWg2RGZRQzNkNHBlbWRnQ1lDYTVRelNlV1p3bndwNWU0ejJsZ2plOFI0MGN0Znp3dTBIUlR2MndDajZMWTlUbDRpX3p1S3FhdHMya3dYU1lWX2Q5Mmd2MzBXMW1nUzlZQzZlRGJ6MDRNOW9HV2IyWTk5RFdWRDJ4aXdWcTFjRVd5bExGa2N3X3NrZWZES3VoSFg5clJIVXZLU1U5SklrVjNxY19XUFY5dkV1SWM?oc=5","date":"2025-05-27","type":"pipeline","source":"businesswire.com","summary":"Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics - businesswire.com","headline":"Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE43ZUFMT3dIVjgwT3BXbDVrWXRGR3p4UENqR1o4QlpUTWV1b1dlSlJQempKWlkzaVp6cDJlZVMwVkR3QjRaNks5OEtISFktRDdKcjE0?oc=5","date":"2025-05-27","type":"pipeline","source":"FirstWord Pharma","summary":"Syndeio debuts with $90M to treat depression, Alzheimer's by repairing synapses - FirstWord Pharma","headline":"Syndeio debuts with $90M to treat depression, Alzheimer's by repairing synapses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNMkNQc2RDaEF2dUJWczBTWFRBUzJ5cDN2RUIyN3dkT2xabVB1aTFSZnplUVZDUmhVS0RwLUx6MjUwT0c3ZUdwUTVyRFZ0Vl9zRU92OWs0dmJNRS1PZE1vWmZQeHdQVFdZTEVZazdBcTFsNUpLSURvdGdRb0hxVjRYZl84X2hCYkwy?oc=5","date":"2025-05-27","type":"pipeline","source":"The Pharma Letter","summary":"Syndeio debuts with $90 million and a synapse-first approach - The Pharma Letter","headline":"Syndeio debuts with $90 million and a synapse-first approach","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}